Teva Pharmaceutical Industries Ltd. March 26 announced that the Food and Drug Administration has approved Qnasl (beclomethasone dipropionate), a new “dry” nasal aerosol corticosteroid that treats seasonal nasal and year-round nasal allergy symptoms in adults and adolescents 12 years old and older.
Qnasl is delivered as a once-daily, pressurized, hydrofluoroalkane (HFA)-propelled nonaqueous aerosol that is environmentally friendly, the Jerusalem-based company said. Previously, only aqueous formulations of corticosteroids were available.
The product is expected to be available by prescription in April, Teva said.
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.